# Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

> **NCT02348723** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 678 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Dabigatran Etexilate 150mg

## Key facts

- **NCT ID:** NCT02348723
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-11-14
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348723, "Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02348723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*